Imagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent

Reuters

02/04

<a href="https://laohu8.com/S/IBXXF">Imagion Biosystems</a> Submits IND Application to FDA for MagSense HER2 Imaging Agent

Imagion Biosystems Ltd. has submitted an Investigational New Drug $(IND)$ application to the U.S. Food and Drug Administration (FDA) for its MagSense® HER2 targeted imaging agent. The company plans to initiate a Phase 2 clinical trial to evaluate the imaging agent for detecting nodal metastases in HER2-positive breast cancer patients, pending FDA approval. Enrollment for the trial could begin as early as the first quarter of 2026, based on historical FDA review timelines. Imagion Biosystems has engaged all necessary strategic trial partners and is advancing logistical preparations in compliance with Good Clinical Practices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imagion Biosystems Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203442564) on February 03, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2608580538"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608580538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608580538?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608580538","market":"us","top_or_hot":-1,"title":"Imagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IBXXF\">Imagion Biosystems</a> Submits IND Application to FDA for MagSense HER2 Imaging Agent\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBXN.AU\">Imagion Biosystems Ltd</a>. has submitted an Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application to the U.S. Food and Drug Administration (FDA) for its MagSense® HER2 targeted imaging agent. The company plans to initiate a Phase 2 clinical trial to evaluate the imaging agent for detecting nodal metastases in HER2-positive breast cancer patients, pending FDA approval. Enrollment for the trial could begin as early as the first quarter of 2026, based on historical FDA review timelines. <a href=\"https://laohu8.com/S/IBX.AU\">Imagion Biosystems</a> has engaged all necessary strategic trial partners and is advancing logistical preparations in compliance with Good Clinical Practices.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IBXDA.AU\">Imagion Biosystems</a> Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203442564) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-04 00:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IBXXF\">Imagion Biosystems</a> Submits IND Application to FDA for MagSense HER2 Imaging Agent\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBXN.AU\">Imagion Biosystems Ltd</a>. has submitted an Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application to the U.S. Food and Drug Administration (FDA) for its MagSense® HER2 targeted imaging agent. The company plans to initiate a Phase 2 clinical trial to evaluate the imaging agent for detecting nodal metastases in HER2-positive breast cancer patients, pending FDA approval. Enrollment for the trial could begin as early as the first quarter of 2026, based on historical FDA review timelines. <a href=\"https://laohu8.com/S/IBX.AU\">Imagion Biosystems</a> has engaged all necessary strategic trial partners and is advancing logistical preparations in compliance with Good Clinical Practices.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IBXDA.AU\">Imagion Biosystems</a> Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203442564) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBX.AU","symbol_name":"Imagion Biosystems","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3fhmTg:1","article_id":"2608580538","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608580538","pubTimestamp":1770136218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Imagion Biosystems Ltd. has submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  for its MagSense HER2 targeted imaging agent. The company plans to initiate a Phase 2 clinical trial to evaluate the imaging agent for detecting nodal metastases in HER2-positive breast cancer patients, pending FDA approval. Enrollment for the trial could begin as early as the first quarter of 2026, based on historical FDA review timelines. Imagion Biosystems has engaged all necessary strategic trial partners and is advancing logistical preparations in compliance with Good Clinical Practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imagion Biosystems Ltd. published the original content used to generate this ne","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBX.AU":"Imagion Biosystems","BK7007":"医疗保健设备"},"translate_title":"Imagion Biosystems向FDA提交MagSense HER2显像剂IND申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBX.AU":0.9},"content_text":"Imagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent\n    \n\nImagion Biosystems Ltd. has submitted an Investigational New Drug $(IND)$ application to the U.S. Food and Drug Administration (FDA) for its MagSense® HER2 targeted imaging agent. The company plans to initiate a Phase 2 clinical trial to evaluate the imaging agent for detecting nodal metastases in HER2-positive breast cancer patients, pending FDA approval. Enrollment for the trial could begin as early as the first quarter of 2026, based on historical FDA review timelines. Imagion Biosystems has engaged all necessary strategic trial partners and is advancing logistical preparations in compliance with Good Clinical Practices.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imagion Biosystems Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203442564) on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}